Given that obesity is a well-established risk factor for breast cancer, even involving the activation of molecular signalling pathways similar to those driving tumour growth, targeting CDK4/6 may provide a unified strategy to counteract both obesity-associated metabolic alterations and cancer progression. Here, CDK4 is linked to cancer.